Tremelimumab, sold under the brand nameImjudo, is a fully humanmonoclonal antibody used for the treatment ofhepatocellular carcinoma (a type of liver cancer).[7][8] Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).[8]
The most common side effects when used in combination with durvalumab include rash, pruritus (itching), diarrhea, abdominal (belly) pain, increased levels of liver enzymes, fever, hypothyroidism (an underactive thyroid gland), cough, peripheral edema (swelling especially of the ankles and feet) and increased level of lipase (an enzyme that helps digest fat, mainly made in the pancreas).[8]
Tremelimumab was approved for medical use in the United States in October 2022,[7][9][10] and in the European Union in February 2023.[8]
Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitizingepidermal growth factor receptor mutations oranaplastic lymphoma kinase positive mutations.[8]
Tremelimumab aims to stimulate an immune system attack on tumors.Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells.[12]
Likeipilimumab, tremelimumab isantibody that binds to the proteinCTLA-4, which is expressed on the surface of activatedT lymphocytes and inhibits the killing of cancer cells.[13] Tremelimumab blocks the binding of theantigen-presenting cell ligandsB7.1 andB7.2 to CTLA-4, resulting in inhibition of B7-CTLA-4-mediated downregulation ofT-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein,CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.[13]
UnlikeIpilimumab (another fully humananti-CTLA-4 monoclonal antibody), which is anIgG1 isotype, tremelimumab is an IgG2 isotype.[14][15]
Phase I and IIclinical studies in metastaticmelanoma showed some responses.[18] However, based on early interim analysis of phase III data,Pfizer designated tremelimumab as a failure and terminated the trial in April 2008.[16][19]
However, within a year, the survival curves showed separation of the treatment and control groups.[20]
Although it was designated in April 2015 asorphan drug status inmesothelioma,[21] tremelimumab failed to improve lifespan in the phase IIb DETERMINE trial, which assessed the drug as a second or third-line treatment for unresectable malignant mesothelioma.[22][23]
In a phase III trial, AstraZeneca paired tremelimumab with a PD-L1 inhibitor,durvalumab, for the first-line treatment ofnon-small cell lung cancer.[24] The trial was conducted across 17 countries, and in July 2017, AstraZeneca announced that it had failed to meet its primary endpoint of progression-free survival.[25]
On 15 December 2022, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Imjudo, intended for the treatment of hepatocellular carcinoma.[26] The applicant for this medicinal product is AstraZeneca AB.[26] Tremelimumab was approved for medical use in the European Union in February 2023.[8][27]
^"Imjudo".Therapeutic Goods Administration (TGA). 29 June 2023. Retrieved10 September 2023.
^"Imjudo (AstraZeneca Pty Ltd)".Therapeutic Goods Administration (TGA). 28 July 2023.Archived from the original on 11 September 2023. Retrieved10 September 2023.
^abcdefgh"Imjudo EPAR".European Medicines Agency (EMA). 9 December 2022.Archived from the original on 3 March 2023. Retrieved2 March 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^Ribas A (June 2012). "Tumor immunotherapy directed at PD-1".The New England Journal of Medicine.366 (26):2517–9.doi:10.1056/NEJMe1205943.PMID22658126.
^ab"Tremelimumab".National Cancer Institute.Archived from the original on 10 August 2019. Retrieved27 October 2022. This article incorporates text from this source, which is in thepublic domain.
^Marshall MA, Ribas A, Huang B (May 2010). "Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma".Journal of Clinical Oncology.28 (15S): 2609.doi:10.1200/jco.2010.28.15_suppl.2609.
^ab"Imjudo: Pending EC decision".European Medicines Agency (EMA). 15 December 2022.Archived from the original on 16 December 2022. Retrieved16 December 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Imjudo Product information".Union Register of medicinal products. 23 February 2023.Archived from the original on 27 February 2023. Retrieved2 March 2023.
^World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59".WHO Drug Information.22 (1).hdl:10665/74120.
N
Y (what is this?) (verify)
This article incorporates text from this source, which is in thepublic domain.
